sharon bml

Post on 10-Apr-2018

232 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

  • 8/8/2019 Sharon Bml

    1/28

    SHARONBIO-MEDICINE

    LIMITED

    CONTENTS

    1

  • 8/8/2019 Sharon Bml

    2/28

    EXECUTIVE SUMMARY

    INTRODUCTION

    SERVICES OF SHARON BIO-MEDICINE

    OBJECTIVE OF THE STUDY

    ABOUT THE INDUSTRY

    ABOUT THE COMPANY

    OPERATIONS OF THE COMPANY LOCATIONS

    FINANCIAL HIGHLIGHTS

    FINDINGS AND LEARNINGS

    MANAGEMENT OF THE COMPANY

    SOCIAL CAUSE UNDERTAKEN BY THE COMPANY

    MAJOR DEVLOPMENTS

    VALUES OF THE COMPANY

    SCOPE FOR FURTHER IMPROVEMENT

    LIMITATIONS TO THE STUDY

    BIBLIOGRAPHY

    EXECUTIVE SUMMARY

    2

  • 8/8/2019 Sharon Bml

    3/28

    Sharon Bio-Medicine Limited, is a fastgrowing Indian Pharmaceutical Companylisted at Bombay Stock Exchange. It isinvolved in manufacturing of Intermediates,Active Pharmaceutical Ingredients andFinished Dosage. Sharon also has recentlystarted an Animal Toxicology Lab Operatingas per GLP requirements.

    Growing at around 50% year on year Sharonnow has an annual turnover of over $100million, a work force of over 500 personnel,operations spanning across seven locations inIndia & one overseas location and a marketpresence in over 40 countries.

    Sharon is predominantly known for itsstrengths in development & manufacturing ofPharmaceutical products in category ofIntermediates & Actives. In 2007 itcommissioned its first Finished productsmanufacturing facility at Dehradoon,Uttarakhand, India.

    Sharons long term focus is to be anintegrated service provider for its customers& adding competitive advantage to itscustomers products throughout its lifecycle.

    INTRODUCTION

    3

  • 8/8/2019 Sharon Bml

    4/28

    Incorporated in 1989 Sharon Bio-MedicineLimited was taken over by the current

    management in 1995. Sharon is a fastgrowing Indian Pharmaceutical, Companylisted at Bombay Stock Exchange. It is mainlyinvolved in manufacturing of Intermediates,Active Pharmaceutical Ingredients andFinished Dosage Forms..

    Sharon is predominantly been known for itsstrengths in development & manufacturing ofPharmaceutical products right fromintermediates to Actives and through tofinished Pharmaceuticals.. Sharon is nowfocusing strongly on developing theRegulated Markets Such as Europe and USA.Sharons Oral Solid dosage in June 2009

    received GMP accreditation by the UK MHRA.

    SERVICES OF SHARON

    4

  • 8/8/2019 Sharon Bml

    5/28

    Preclinical Toxicology (Offered by SA-FORD-A Division of Sharon Bio Medicine)

    Chemical Process Development & Scale up Formulation Development Analytical Method Development DMF & Dossier preparation. (Sharon alsoundertakes joint development projects forANDA & CTD Dossiers)

    Commercial Manufacturing ofIntermediates, Actives, Finished Dosages.

    Stability monitoring for the entire shelf lifeof the product.

    OBJECTIVE OF THE STUDY

    5

  • 8/8/2019 Sharon Bml

    6/28

    1. TO UNDERSTAND THE COMPANY IN DETAIL.

    2. TO MAKE FUNDAMENTAL ANALYSIS OF THECOMPANY.

    3. ANALYSING THE COMPANY AS WHOLE.

    4. TO FIND OUT THE CURRENT STATUS OF THECOMPANY.

    ABOUT THE INDUSTRY

    India is the world's fourth largest producer ofpharmaceuticals by volume, accounting foraround 8% of global production. In valueterms, production accounts for around 1.5%of the world total. The Indian pharmaceuticalindustry directly employs around 500,000

    people and is highly fragmented. While thereare around 270 large R&D based

    6

  • 8/8/2019 Sharon Bml

    7/28

    pharmaceutical companies in India, includingmultinationals, government-owned andprivate companies, there are also around5,600 smaller licensed genericsmanufacturers, although in reality onlyaround 3,000 companies are involved inpharmaceutical production. Most small firmsdo not have their own production facilities,but operate using the spare capacity of otherdrug manufacturers.

    The advent of pharmaceutical product patentrecognition in January 2005 changed theground rules for Indian companies. In the runup to the new post-patent era and since, theIndian industry has been evolving. R&Ddepartments are moving away from reverse-engineering in favour of developing novel

    drug delivery systems and discoveryresearch.

    ABOUT THE COMPANY

    SHARON BIO-MEDICINE LIMITED (SBML) wasincorporated in the year 1989 as SharonSynthochem Pvt. Ltd.(SSPL) to manufacturePharmaIntermediates. SSPL was originally promotedby Mrs.

    7

  • 8/8/2019 Sharon Bml

    8/28

    Anita Sunthankar and Mr. Anant VithalSunthankar. due to liquidity crunch, it wastaken over by Mr.Hemant M Shah andMr.Kaushik M Shah. With continuing liquiditycrunch and lack of technical expertise, it wastaken over by the present management Mrs.Savita Gowda and Mr. Mohan P Kala in theyear 1995. The management changed thename of the company to Sharon Bio-MedicineLimited on 28th August 2001.

    During the year 2000, SBM established itsR&D divisionwith focus on process research anddevelopment. The company created thefacilities without altering the production line.After getting into bulk drug and drugintermediates the company went public withissue size of Rs.2.5crore in March 2000.Theissue wasoversubscribed by 3.85 times. The fundsraised fromissue were utilized to set up R& D block tocarry outprocess synthesis for API's andintermediates. DuringFY07 SBM issued 1.5lac equity shares ofRs.10eachto Mauritius based company M/s PharmtakLimited atthe rate of Rs.300 per share.

    HISTORY OF THE COMPANY

    8

  • 8/8/2019 Sharon Bml

    9/28

    1997- Started manufacturing APIs-

    launched its first drug TRIMETAZIDINEDI HYDROCHLORIDE (cardiovasculardrug).

    2000- Came with public offering of 25%shares issue was oversubscribed by3.85times.Set up a R&D block to carryout process synthesis for APIS

    intermediates.

    2005- Hon. Finance Minister of IndiaSHRI.P.CHIDAMBARAM had put thecompany on INDO NEXT at BOMBAYSTOCK EXCHANGE; company wasawarded with ISO 9001-2000accredation by BVQI-UKAS & BVQI-

    ANAR.

    2006- Construction of a state of the ArtFormulation Unit for oral dosage startedat Dehradun estimated cost of theproject: $8million.

    2007- Commissioning of the formulation

    plant started supplying formulations toreputed Pharmaceutical companies inIndia on contract manufacturing basis.

    2009- Set up & operationalised a newbusiness division by name SA-FORDdedicated to Toxicological studies. Setup & operationalised of the ART APIplant (unit-2) at Taloja.

    9

  • 8/8/2019 Sharon Bml

    10/28

    OPERATIONS OF THE

    COMPANY

    SBML is involved in the manufacturing andmarketingof Active Pharmaceutical Ingredients (API)and APIintermediates for the cardiovascular, anti-fungal, antidiabetic and anti-hypertensiondrugs. SBML started manufacturing APIs bylaunching its first drugTrimetazidine di hydrochloride(Cardiovascular Drug)in the year 1997.

    The company now manufactures 20 APIs and35chemical intermediates along withformulations at their manufacturing facilities.The manufacturing facilities are located atTaloja, Maharastra (dedicated for producingAPI supplied to unregulated markets) andUttaranchal, Dehradoon (for formulations andinjectibles). As a part of forward integrationand expansion, SBML started formulation unitat Dehradoon, Uttaranchal at an estimatedcost of USD 8 mn. The commercial productionof formulation unit started in the month ofApril 2007 with oral solid dosage facility.

    10

  • 8/8/2019 Sharon Bml

    11/28

    SBML's facilities are ISO 9001-2000 certifiedand accredited by BVQI - UKAS & BVQI - ANAB

    LOCATIONS OF SBML

    Site Place Details Number of Employees

    Corporate Office

    Vashi All manufacturinglocations are controlledfrom this location. Thisis where the Marketing,Supply Chain, Accounts,Corporate HR,Corporate QualityAssurance andRegulatory Affairsteams are based.

    85

    Finance Office Andheri The finance departmentof the company is basedin Andheri West.

    15

    Research &Development

    Taloja This is where theAnalytical, SyntheticChemistry and Oralsolid formulationdevelopment is carriedout.

    30

    11

  • 8/8/2019 Sharon Bml

    12/28

    ToxicologyCentre

    Taloja Operating under thedivision SAFORD, this iswhere the companycarries out specializedtesting using animals.

    25

    API Unit 1 Taloja The companys firstManufacturing Unit hasbeen operational since1995. Mainly focuses onmanufacturingIntermediates & APIs.The site has ISOcertification and is alsoLocal GMP certified.

    100

    API Unit 2 Taloja Commissioned recentlyin end 2009 thisManufacturing Unit isfocused more oncatering to regulatedmarkets such as SouthKorea, South Africa,Europe, USA etc

    125

    FormulationUnit 1

    Dehradoon

    Commissioned in Mid2007 this was thecompanys foray intoManufacturing offinished products. TheUnit has a capacity ofmanufacturing 2500million tablets and 500million capsules. Theunit is certified byauthorities such as

    125

    12

  • 8/8/2019 Sharon Bml

    13/28

    WHO, Invima Colombia,UK MHRA etc.

    FINANCIAL HIGHLIGHTS OF THECOMPANY

    (in lacs)05-06 06-07 07-08 08-09

    TURNOVER 8911.

    27

    17100.

    45

    33461

    .6

    41979.

    12OTHERINCOMES

    15.34 51.22 250.51

    183.23

    PBDIT 1403.42

    2637.15

    4158.03

    4073.33

    DEPRECIATION

    55.70 117.92 359.96

    417.90

    INTEREST 63.48 249.88 658.70

    1436.32

    PBT 1284.24

    2269.35

    3139.37

    2219.11

    TAX 202.75

    478.00 407.00

    310.00

    PAT 1072.90

    1777.28

    2718.79